Compare AbbVie Inc (ABBV) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

SHY trades at $81.98 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.24 per share quarterly. Recent bond market focus highlights investor interest in Treasury income products amid rising yield expectations and Federal Reserve policy uncertainty.

The outlook remains cautious given bearish technical signals and bond market volatility. Investment opportunity exists for income-focused investors seeking Treasury exposure, though risks include interest rate sensitivity and Fed policy shifts. Current market conditions favor defensive positioning with attention to yield curve movements.